Market Overview

Sydney, Australia – December 19, 2025 – The Australia vaccine market has demonstrated exceptional growth momentum, with the market valued at USD 1,305.43 Million in 2025 and projected to reach USD 2,785.10 Million by 2034, expanding at a compound annual growth rate (CAGR) of 8.78% during the forecast period from 2026 to 2034. This robust expansion is propelled by the nation's comprehensive National Immunisation Program, increasing infectious disease prevalence, technological innovations in vaccine development, and substantial government investment in pandemic preparedness and domestic manufacturing infrastructure.

The Australian vaccine market is experiencing robust expansion driven by the convergence of demographic aging, heightened public health awareness, and strategic infrastructure investments fundamentally reshaping the competitive landscape. The market demonstrates remarkable momentum, supported by growing public health awareness, rising infectious disease prevalence, and comprehensive national immunization programs targeting populations across the lifespan. In June 2025, the Australian Government launched the National Immunization Strategy for Australia 2025-2030, setting out six key priority areas to increase and sustain immunization uptake, strengthen trust in vaccines, and improve equitable access particularly for Aboriginal and Torres Strait Islander communities.

Key Market Drivers

Expansion of Domestic Vaccine Manufacturing Infrastructure

Australia is witnessing significant expansion in domestic vaccine manufacturing capabilities, with substantial investments in advanced production facilities. The CSL Seqirus facility in Tullamarine represents the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere, creating a supply chain worth more than AUD 300 Million annually to the Australian economy. In December 2024, CSL Seqirus opened its AUD 800 Million cell-based influenza vaccine manufacturing facility, establishing production capability with capacity for seasonal and pandemic influenza vaccines under a long-term agreement with the Australian Government. Additionally, Moderna's partnership with the Australian Government to build an mRNA vaccine manufacturing facility in Victoria, expected to produce up to 100 million vaccine doses annually, further strengthens the nation's sovereign manufacturing capabilities and pandemic preparedness infrastructure.

Introduction of Novel RSV Prevention Programs

The landscape of respiratory syncytial virus prevention in Australia evolved significantly with the introduction of maternal RSV vaccination and infant monoclonal antibody programs. The National RSV Mother and Infant Protection Program commenced in February 2025, providing pregnant women with free access to the Abrysvo vaccine under the National Immunisation Program. Complementary state-funded programs provide nirsevimab to eligible infants, with early real-world data demonstrating substantial effectiveness against RSV-associated hospitalisation, resulting in significantly fewer RSV-related hospital admissions than initially forecast during the initial rollout season. Western Australia data showed nirsevimab effectiveness of 88.2% against RSV-associated hospitalization, corresponding to 57% fewer hospitalisations than forecast predictions.

Expansion of Pharmacy Vaccination Services

The Australian Government's implementation of the National Immunisation Program Vaccinations in Pharmacy (NIPVIP) Program from January 2024 has transformed vaccine accessibility across the nation. Participating pharmacies receive payments of AUD 18.85 per vaccination for administering NIP vaccines, enabling eligible individuals aged five years and over to access free vaccinations at community pharmacies. This expansion has been accompanied by broadening pharmacist vaccination scopes across states and territories, with Victorian intern pharmacists now authorised to administer vaccines under supervision, significantly expanding the immunisation workforce capacity.

Market Segmentation

By Technology:

1. Inactivated and Subunit Vaccines (30% market share in 2025)

2. Conjugate Vaccines

3. Live Attenuated Vaccines

4. Recombinant Vaccines

5. Toxoid Vaccines

6. Others

By Patient Type:

1. Paediatric (60% market share in 2025)

2. Adult

By Indication:

1. Bacterial Diseases (55% market share in 2025)

   1. Meningococcal Disease, Pneumococcal Disease, DPT, Tuberculosis, Hib, Typhoid, Others

2. Viral Diseases

   1. Hepatitis, Influenza, HPV, MMR, Rotavirus, Herpes Zoster, Varicella, Japanese Encephalitis, Polio, Rabies, Dengue, Others

By Route of Administration:

1. Intramuscular and Subcutaneous (70% market share in 2025)

2. Oral Administration

3. Others

By Product Type:

1. Multivalent Vaccine (65% market share in 2025)

2. Monovalent Vaccine

By Treatment Type:

1. Preventive Vaccine (80% market share in 2025)

2. Therapeutic Vaccine

By Distribution Channel:

1. Hospital Pharmacies (35% market share in 2025)

2. Retail Pharmacies

3. Institutional Sales

4. Others

By End User:

1. Hospitals (40% market share in 2025)

2. Clinics

3. Vaccination Centers

4. Academic and Research Institutes

5. Others

By Region:

1. Australia Capital Territory & New South Wales

2. Victoria & Tasmania

3. Queensland

4. Northern Territory & Southern Australia

5. Western Australia

Request Sample Report: https://www.imarcgroup.com/australia-vaccine-market

Key Market Insights

Inactivated and Subunit Vaccines Lead Technology Segment

Inactivated and subunit vaccines dominate with a 30% market share in 2025, encompassing seasonal influenza vaccines, pneumococcal conjugate vaccines, and hepatitis vaccines that form integral components of the National Immunization Program. Cell-based manufacturing technology offers significant advantages including faster scale-up capabilities for pandemic response, reduced production timelines, and elimination of egg-related allergen concerns.

Paediatric Segment Dominates Patient Type

The paediatric vaccination segment leads with 60% market share in 2025, encompassing comprehensive immunization programs targeting infants, children, and adolescents through scheduled vaccinations. According to the National Centre for Immunization Research and Surveillance, childhood vaccination coverage rates in 2024 stood at 91.6% for one-year-olds, 89.4% for two-year-olds, and 92.7% for five-year-olds. From September 2025, the National Immunization Program transitioned from Prevenar 13 to Prevenar 20 (20-valent pneumococcal conjugate vaccine) for children, expected to prevent 25-30% more cases of invasive pneumococcal disease compared to the previous formulation.

Bacterial Diseases Lead Indication Segment

Bacterial disease vaccines constitute 55% market share in 2025, encompassing pneumococcal, meningococcal, pertussis, and other bacterial pathogen vaccines. From July 2024, the meningococcal ACWY vaccine MenQuadfi was funded on the National Immunisation Program, replacing Nimenrix for the adolescent age group, while state-funded meningococcal B vaccination programs continue in South Australia and Queensland.

Multivalent Vaccines Dominate Product Type

Multivalent vaccines represent 65% market share in 2025, combining protection against multiple pathogens within single formulations to optimize immunization efficiency and patient compliance. Quadrivalent influenza vaccines have become standard for seasonal immunization programs, with the 2025 season offering multiple options including both egg-based and cell-based formulations.

Preventive Vaccines Hold Largest Treatment Share

Preventive vaccines constitute 80% of market share in 2025, reflecting Australia's public health focus on disease prevention through prophylactic immunization strategies. The National Immunization Strategy for Australia 2025-2030 establishes a framework for reducing the impact of vaccine-preventable diseases through high uptake of safe, effective, and equitable immunization programs.

Regional Analysis

Australia Capital Territory & New South Wales dominates the market, driven by the largest population base concentrated in Sydney metropolitan area, extensive healthcare infrastructure, leading research institutions, and comprehensive immunization service networks.

Victoria & Tasmania represents significant market share, supported by Melbourne's advanced healthcare ecosystem, presence of major vaccine manufacturing facilities including CSL Seqirus operations, strong pharmaceutical research capabilities, and well-established immunization delivery networks.

Queensland holds substantial market presence, driven by tropical disease vaccination requirements, state-funded meningococcal B programs, growing population demographics, and proactive public health immunization initiatives.

Northern Territory & South Australia demonstrates steady growth, characterized by targeted vaccination programs for Aboriginal and Torres Strait Islander communities, remote area immunization services, and South Australia's state-funded meningococcal B program.

Western Australia exhibits notable market growth, supported by pioneering RSV immunization programs demonstrating strong effectiveness outcomes, expanding pharmacy vaccination services, and innovative public health delivery models.

Growth Drivers in Detail

Rising Infectious Disease Burden Driving Immunization Demand

Australia experienced unprecedented infectious disease activity during 2024, with record-breaking respiratory illness seasons fundamentally reshaping vaccine demand patterns. Between January 1 and October 2024, 349,728 influenza alerts were registered, making the 2024 flu season the worst since 2019. This dramatic disease burden has heightened awareness of vaccine importance among healthcare providers, policymakers, and the general population, driving increased investment in immunization infrastructure and expanded vaccination programs.

Strategic Government Investment in Domestic Manufacturing

The Australian Government has made substantial investments to strengthen sovereign vaccine manufacturing capabilities, enhancing pandemic preparedness and reducing reliance on international supply chains. These investments create structural market growth drivers through expanded local production capacity, reduced import dependency, and enhanced ability to respond rapidly to emerging health threats.

Expansion of National Immunization Program Coverage

Continuous expansion of the National Immunization Program to incorporate new vaccines and extend eligibility criteria drives sustained market growth. The February 2025 introduction of the National RSV Mother and Infant Protection Program provides free maternal RSV vaccination, while the September 2025 transition to Prevenar 20 expands pneumococcal protection to additional serotypes.

Market Challenges

Despite strong growth prospects, the market faces several challenges including declining vaccination coverage rates across age groups, with childhood vaccination coverage at 24 months dropping below 90% in 2024 for the first time since 2016. Vaccine hesitancy and misinformation continue to present significant challenges, with low levels of trust associated with vaccine skepticism. Supply chain vulnerabilities and international dependencies for certain products create vulnerability to global supply disruptions and manufacturing delays.

Recent Development

In February 2025, the National RSV Mother and Infant Protection Program commenced, providing pregnant women free access to Abrysvo vaccine under the National Immunisation Program. Early real-world data from Western Australia demonstrated nirsevimab effectiveness of 88.2% against RSV-associated hospitalization, corresponding to 57% fewer hospitalisations than forecast predictions.

Competitive Landscape

The Australia vaccine market exhibits competitive intensity characterized by the presence of multinational pharmaceutical corporations alongside domestic manufacturers competing across technology platforms, indication categories, and distribution channels. Market dynamics reflect strategic positioning across mRNA, protein-based, and traditional vaccine technologies, with leading companies maintaining significant market presence through domestic manufacturing capabilities, government partnership arrangements, and technological innovation.

Market Outlook

The Australia vaccine market is poised for sustained expansion over the forecast period, underpinned by strategic government initiatives, expanding immunisation schedules, and ongoing investment in domestic manufacturing infrastructure. The National Immunization Strategy 2025-2030 provides comprehensive guidance for vaccine access, establishing a vision for a healthier Australia through immunization and reducing the impact of vaccine-preventable diseases through high uptake of safe, effective, and equitable programs.

About IMARC Group

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group 134 N 4th St. Brooklyn, NY 11249, USA Email: sales@imarcgroup.com Tel No: (D) +91 120 433 0800 United States: +1-201-971-6302

Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Ask an Analyst: https://www.imarcgroup.com/request?type=report&id=32305&flag=C